Neoadjuvant_chemotherapy_for_nonmetastatic_osteosarcoma_of_the_extremities._Between_September_1986_and_December_1988,_125_patients_with_osteosarcoma_of_the_extremities_entered_the_second_neoadjuvant_study_at_the_authors'_institution._Patients_received_preoperatively_two_cycles_of_methotrexate_(MTX)_intravenously,_followed_by_cisplatinum_(CDP)_intraarterially,_plus_adriamycin_(ADM)_intravenously._After_surgery,_the_patients_classified_as_"good_responders"_(more_than_90%_tumor_necrosis)_received_ADM,_MTX,_and_CDP,_while_the_"poor_responders"_(less_than_90%_tumor_necrosis)_had_a_longer_chemotherapy_that_included_ifosfamide_and_etoposide_(VP-16)_in_addition_to_MTX,_ADM,_and_CDP._Limb_salvage_was_possible_in_85%_of_patients,_8%_had_an_amputation,_and_7%_had_a_rotationplasty._The_surgical_margins_were_adequate_(radical_or_wide)_in_88%_of_cases_and_inadequate_(marginal_or_intralesional)_in_12%._At_an_average_follow-up_period_of_28_months_(range,_13_to_41),_109_patients_(87%)_remained_continuously_disease_free,_15_(12%)_relapsed_with_pulmonary_metastases,_and_one_patient_(0.8%)_had_a_local_recurrence._Compared_with_the_first_neoadjuvant_study_at_the_authors'_institution_that_used_only_MTX_and_CDP_preoperatively,_the_percentage_of_limb_salvages,_"good_responders,"_and_continuously_disease-free_survival_at_two_years_was_significantly_higher_in_the_second_Rizzoli_neoadjuvant_study_(85%,_74%,_and_87%_versus_77%,_52%,_and_59%)._Systemic_toxicity_because_of_chemotherapy_was_superimposable._A_retrospective_analysis_of_the_real_dose_intensity_for_each_patient_demonstrated_a_correlation_between_the_intensity_of_chemotherapy_and_prognosis.